NLN Pharmacology Practice Exam

The key idea is that the old FDA pregnancy category system reduced complex fetal risk information to a single letter, which oversimplified risk and could mislead clinicians. A drug’s letter didn’t convey how risk varied with timing of exposure, dose, or the strength of the underlying data, nor did it help weigh whether treating the mother’s condition was worth potential fetal risk. Today, risk is assessed by using detailed labeling that provides a narrative discussion of pregnancy data, including study types, outcomes, timing considerations, and specific clinical context, plus trimester-specific information and practical guidance. Clinicians integrate this with the patient’s situation, disease severity, available alternatives, pharmacokinetics, and pregnancy registries to make a thoughtful risk-benefit decision. Since labeling was updated under the Pregnancy and Lactation Labeling Rule, risk assessment has shifted away from a single category to a nuanced, case-by-case approach guided by current guidelines.